HUYA Bioscience Int’l Announces First Pre-IND Outcome For A Development Stage Compound Sourced From China – HBI-8000, Promising New Cancer Compound
HUYA Bioscience Int’l Announces First Pre-IND Outcome For A Development Stage Compound Sourced From China – HBI-8000, Promising New Cancer Compound
FDA feedback validates HUYA’s Integrated Co-Development Model for China-sourced Drug Candidates
San Diego, CA, USA – April 14, 2008 — HUYA Bioscience International (HUYA), the leader in U.S./China pharmaceutical co-development, today announced the outcome of the first pre-IND (Investigational New Drug) consultation with the U.S. FDA for a development-stage compound sourced from China.